Stocks · News reference
Wells Fargo Maintains Hold Rating and $5 Price Target for Zentalis Pharmaceuticals
Wells Fargo analyst Yanan Zhu has maintained a Hold rating and a $5 price target on Zentalis Pharmaceuticals.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Upgrades Zentalis Pharmaceuticals to Outperform
Wedbush upgraded Zentalis Pharmaceuticals from Neutral to Outperform and increased its price target for the company's stock to $6 from $5.
Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results
Zentalis Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting a cash position of $228.9 million.
Zentalis Pharma Q3 EPS $(0.34) Beats $(0.53) Estimate
8-K filing — Zentalis Pharmaceuticals, Inc. (ZNTL)
Filed: 2026-11-09 AccNo: 0001725160-26-000069 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure
Zentalis Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Zentalis Pharmaceuticals announced that its management team will participate in two investor conferences in November 2026.